Psychopharmacology - Module 2: PsyPharm & ADHD

Certificate of Completion. This session does not offer BACB continuing education (CE) credit.

In this webinar, we focus on evidence-based assessment, diagnosis, and treatment of ADHD, emphasizing behavioral and psychopharmacological strategies. Research has shown year after year that the combination of behavioral and psychopharmacology has been the most effective in reaching positive treatment outcomes. We also discuss and dispel myths surrounding ADHD and discuss the negative outcomes if a child is left untreated. We also explore how ADHD is often diagnosed along with other disorders, including learning disabilities, mood disorders, Autism Spectrum Disorders, anxiety, and depression.

Through examining real-world scenarios that highlight the implications and outcomes of children diagnosed with ADHD, we gain a better understanding of how to assess, diagnose, treat, and evaluate outcomes for these children and their families. Finally, we share the importance of integrated care for these children and their families, including pediatricians and nurse practitioners, mental health specialists and psychiatrists, behavioral specialists, speech and occupational therapists, and educators.

Presenter: Ronald T. Brown, Ph.D., ABPP Deborah P. Coehlo, Ph.D., C-PNP, PMHS, CFLE

Learning Objectives: 

1. Recognize specific target behaviors associated with ADHD for which psychopharmacology is effective.
2. Identify classes of psychotropic agents that have demonstrated effectiveness in the treatment of ADHD
3. Understand common medications used in the treatment of ADHD, including the indication, mechanism of action, adverse and side effects, and monitoring criteria
4. Explore and discuss the most effective behavior strategies that are seen throughout various developmental stages of treatment for ADHD.
5. Apply knowledge to specific case studies including assessment, diagnosis, treatment, and evaluation of outcomes.
6. Identify skills required to approach parents about the potential benefits of psychotropic medication for their children.

TIMELINE: This course, on its own has a license for active use for 30 days unless it is purchased as part of a bundle/library.

MANDATORY DISCLAIMER: The Behavior Analyst Certification Board (“BACB”) does not sponsor, approve, or endorse Special Learning, the materials, information, or sessions identified herein.

Want unlimited training? Get All Access training HERE. For cancellations and refunds, please see our return policy.